![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY
u
aDepartment of Experimental Medicine (N.R., I.R., M.A., A.D.F., D.F., A.T.), Department of Surgery (A.A.), and Department of Basic and Applied Biology (M.B.), University of L'Aquila, L'Aquila, Italy; and Novartis Pharma Research, Therapeutic Area Arthritis and Bone Metabolism, Basel, Switzerland (M.S., D.F.)
c-Src is a proto-oncogene, belonging to the nonreceptor protein kinases family, which plays a prominent role in carcinogenesis. In this study, we tested the hypothesis that c-Src could promote breast cancer metastasis acting on several cell types and that pharmacological disruption of its kinase activity could be beneficial for the treatment of metastases. Female BALB/c-nu/nu mice were subjected to intracardiac injection of the human breast cancer cells MDA-MB-231 (MDA-231), which induced prominent bone and visceral metastases. These were pharmacologically reduced by treatment with the c-Src inhibitor [7-{4-[2-(2-methoxy-ethylamino-ethoxy]-phenyl}-5-(3-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine] CGP76030 (100 mg/kg/day p.o.), resulting in decreased morbidity and lethality. Metastases were more severe in mice injected with MDA-231 cells stably transfected with wild-type c-Src (MDA-231-SrcWT), whereas transfection in injected cells of a c-Src kinase-dead dominant-negative construct (MDA-231-SrcDN) resulted in reduced morbidity, lethality, and incidence of metastases similar to the mice treated with the inhibitor. An analogous beneficial effect of c-Src inhibition was observed in subcutaneous and intratibial implanted tumors. In vitro, c-Src suppression reduced MDA-231 cell aggressiveness. It also impaired osteoclast bone resorption both directly and by reducing expression by osteoblasts of the osteoclastogenic cytokines interleukin-1
and interleukin-6, whereas parathyroid hormone-related peptide was not implicated. c-Src was also modestly but consistently involved in the enhancement of endothelial cell proliferation in vitro and angiogenesis in vivo. In conclusion, we propose that c-Src disruption affects the metastatic process and thus is a therapeutic target for the treatment of breast cancer.
Address correspondence to: Dr. Anna Teti, Department of Experimental Medicine, Via Vetoio-Coppito 2, 67100 L'Aquila, Italy. E-mail: teti{at}univaq.it
This article has been cited by other articles:
|
|
 |
|
  T. J. de Vries, M. G. Mullender, M. A. van Duin, C. M. Semeins, N. James, T. P. Green, V. Everts, and J. Klein-Nulend The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts Mol. Cancer Res., April 1, 2009; 7(4): 476 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Balosso, M. Maroso, M. Sanchez-Alavez, T. Ravizza, A. Frasca, T. Bartfai, and A. Vezzani A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1{beta} Brain, December 1, 2008; 131(12): 3256 - 3265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Akiyama, C. R. Dass, and P. F.M. Choong Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway Mol. Cancer Ther., November 1, 2008; 7(11): 3461 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schramp, O. Ying, T. Y. Kim, and G. S. Martin ERK5 promotes Src-induced podosome formation by limiting Rho activation J. Cell Biol., October 22, 2008; 181(7): 1195 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vultur, R. Buettner, C. Kowolik, W. Liang, D. Smith, F. Boschelli, and R. Jove SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells Mol. Cancer Ther., May 1, 2008; 7(5): 1185 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tauzin, H. Ding, K. Khatib, I. Ahmad, D. Burdevet, G. van Echten-Deckert, J. A. Lindquist, B. Schraven, N.-u. Din, B. Borisch, et al. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts Blood, February 15, 2008; 111(4): 2310 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Matteucci, E. Ridolfi, P. Maroni, P. Bendinelli, and M. A. Desiderio c-Src/Histone Deacetylase 3 Interaction Is Crucial for Hepatocyte Growth Factor Dependent Decrease of CXCR4 Expression in Highly Invasive Breast Tumor Cells Mol. Cancer Res., August 1, 2007; 5(8): 833 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Carnevale, C. J. Proietti, M. Salatino, A. Urtreger, G. Peluffo, D. P. Edwards, V. Boonyaratanakornkit, E. H. Charreau, E. B. de Kier Joffe, R. Schillaci, et al. Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways Mol. Endocrinol., June 1, 2007; 21(6): 1335 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jin, C. Yun, A. Hobbie, M. J. Martin, P. H.B. Sorensen, and S.-J. Kim Cellular Transformation and Activation of the Phosphoinositide-3-Kinase-Akt Cascade by the ETV6-NTRK3 Chimeric Tyrosine Kinase Requires c-Src Cancer Res., April 1, 2007; 67(7): 3192 - 3200. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
